You are here
Phase 3 Studies Initiated for Telavancin in Hospital Acquired Pneumonia
Telavancin, a rapidly bactericidal injectable antibiotic with multiple mechanisms of action, is a novel lipoglycopeptide that was discovered by Theravance through the application of multivalent drug design in a research program dedicated to finding new antibiotics for serious infections due to Staphylococcus aureus (including multi-drug resistant strains) and other Gram- positive pathogens. In addition to hospital acquired pneumonia, telavancin is currently in Phase 3 studies for the treatment of complicated skin and skin structure infections (cSSSI).
Previously presented data have demonstrated that the bactericidal activity of telavancin against S. aureus is mediated by multiple mechanisms. This antibacterial activity results from interaction with D-Ala-D-Ala-containing peptidoglycan intermediates that leads, at submicromolar concentrations, to inhibition of the transglycosylation step of peptidoglycan synthesis during cell wall synthesis. Also, at higher, clinically-achievable concentrations, direct effects on bacterial membrane function, such as dissipation of membrane and increased permeability, are observed.
Source: Theravance, Inc.